Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 7/20 | 0.41 |
| ▸ | WNT3A | P56704 | 7/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6133646 | 0.85 | PTPN1 (0.39) | CTNNB1WNT3AGAAPOLBNPC1 | |
| SCHEMBL6539165 | 0.81 | POLB (0.38) | LMNAGAAPOLBNPC1RAB9A | |
| SCHEMBL6134014 | 0.71 | CNR2 (0.35) | CTNNB1WNT3ARECQLLMNAGAA | |
| SCHEMBL6134012 | 0.71 | CNR2 (0.35) | CTNNB1WNT3ARECQLLMNAGAA | |
| SCHEMBL23370058 | 0.70 | POLB (0.36) | POLBP2RX7 | |
| SCHEMBL21630213 | 0.69 | CTNNB1 (0.48) | CTNNB1WNT3ALMNAGAACNR2 | |
| SCHEMBL6133993 | 0.67 | FFAR1 (0.36) | ESR1 | |
| SCHEMBL29410857 | 0.67 | CTNNB1 (0.57) | CTNNB1WNT3ALMNAGAACNR2 | |
| SCHEMBL1950901 | 0.67 | CTNNB1 (0.57) | CTNNB1WNT3ALMNAGAACNR2 | |
| SCHEMBL30089582 | 0.66 | CTNNB1 (0.75) | CTNNB1WNT3ALMNAGAACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
| WO-2003057689-A1 | AMINOPYRIMIDINE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | CTNNB1 419/4885WNT3A 1566/4885RECQL 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.